NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical…
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company…
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Canopy, the leader in Enterprise AI for oncology, today announced a partnership with…
RELiZORB is now available for patients of all ages to hydrolyze fats during enteral feeding WALTHAM, Mass., Nov. 3, 2025…
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech…
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has…
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma,…
November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient…